| Outcome Measures: |
Primary: Change in A1c at the End of Study Period, change in A1c (%) from baseline to end of study at 16 weeks, 16 weeks (from baseline to end of study at 16 weeks) | Secondary: Changes in Weight, change (in pounds) from baseline to the end of study at 16 weeks, 16 weeks (from baseline to end of study at 16 weeks)|Changes in Blood Pressure, change (mmHg) of systolic BP from baseline to the end of study at 16 weeks, 16 weeks (from baseline to end of study at 16 weeks)|Changes in Heart Rate, change (beats/min) from baseline to the end of study at 16 weeks, 16 weeks|Changes in LDL, change (mg/dL) from baseline to the end of study at 16 weeks, 16 weeks (from baseline to end of study at 16 weeks)|Changes in Total Cholesterol, change (mg/dL) from baseline to the end of study at 16 weeks, 16 weeks (from baseline to end of study at 16 weeks)|Changes in Serum Creatinine, change (mg/dL) from baseline to the end of study at 16 weeks, 16 weeks (from baseline to end of study at 16 weeks)|Changes in Treatment Satisfaction Scores (DM-SAT Total Score), Patient satisfaction with treatment in both groups will be measured by the validated the Diabetes Medications Satisfaction Tool (DM-SAT). Response options range from 0="not at all satisfied" to 10="extremely satisfied" and a total score is calculated ranging from 0 to 100, with higher scores indicating more diabetes medication satisfaction., 16 weeks (from baseline to end of study at 16 weeks)
|
